Medicaps Limited

BSE: 523144
Medicaps Limited - pharma in Indore, Madhya Pradesh, India. FY 2026 financials and compliance.
CIN L70100MP1983PLC002231 Incorporated 06 August 1983 ROC Gwalior HQ Indore, Madhya Pradesh, India
Active Listed - BSE: 523144 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹12.45 Cr
▼ 51.14% YoY
Computed EBITDA · FY 2026
-₹1.2 Cr
▼ 233.3% YoY
Net profit · FY 2026
-₹3.04 Cr
▼ 431.96% YoY
Authorised capital
₹15 Cr
Registered with MCA
Paid-up capital
₹12.47 Cr
Issued & subscribed
Open charges
₹20 Lakh
Satisfied ₹2.22 Cr
Company age
43 yrs
Est. 1983
Employees · EPFO
2
Latest available

About Medicaps Limited

Data last updated: 14 July 2026

Medicaps Limited is a public limited company based in Indore, Madhya Pradesh, India, recognised as a startup by DPIIT. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 06 August 1983, the company has been in operation for over 43 years.

Registered with ROC Gwalior under CIN U24232MP1983PLC002231. Listed on BSE: 523144.

Capital: an authorised share capital of ₹15 Cr and a paid-up capital of ₹12.47 Cr. Formerly known as Medicaps Pvt Limited. It is led by directors including Alok K Garg and Ramesh Chandra Mittal.

Last AGM: 18 September 2025. Financial statements filed for year ended 31 March 2025. Office: Indore, Madhya Pradesh.

As per BSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹12.45 Cr, a decline of 51.14% compared to the previous year. The net worth stands at ₹111.61 Cr (down 7.97% YoY). Total assets are valued at ₹115.46 Cr (down 7.94% YoY).

The company has a workforce of approximately 2 employees as per the latest available data.

The company is associated with 1 brand - Medi-Caps. As per MCA filings, the company has open charges of ₹20 Lakh and satisfied charges of ₹2.22 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website medicaps.com.

Company Details of Medicaps Limited
CIN L70100MP1983PLC002231
Registration Number 002231
Incorporation Date 06 August 1983
ROC Gwalior
Listing Status Listed (BSE: 523144)
Company Status Active
Date of Last AGM 18 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
DPIIT Recognition Recognised Startup
Key People
Alok K Garg Managing Director Ramesh Chandra Mittal Director Ashok Agrawal Omprakash Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    Locked
  • Social Media
    Locked
  • Registered Address
    201 Pushpratna Paradise, 9/5 New Palasiya, Indore, Madhya Pradesh, India – 452001
  • Industry
    Pharma, Drug Formulation & Development
Company report
Medicaps Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Medicaps Limited report

Financials, compliance, directors, charges, ownership and filings for Medicaps Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Medicaps Limited

Medicaps Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L70100MP1983PLC002231, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L70100MP1983PLC002231 Current
U24232MP1983PLC002231 Previous
L24232MP1983PLC002231 Previous

Associated Brands with Medicaps Limited

Medicaps Limited operates one associated brand: Medi-Caps. These brands represent Medicaps Limited's diversified market presence and brand portfolio.

Brand Description Website
Medi-Caps
Manufacturer of empty gelatin capsules medicaps.com

Competitors & Alternatives of Medicaps Limited

Brands and companies operating in the same space as Medicaps Limited include Inventia Healthcare, Zim Labs, Lotus and 7 more.

Competitor Description Location Founded
Inventia Healthcare Inventia Healthcare Oral solid drug delivery systems are manufactured and developed. Mumbai, India, India 1985
Zim Labs Zim Labs Solid and semisolid dosage forms are developed and manufactured. Nagpur, India, India 1989
Lotus Lotus Contract manufacturing for oral solid formulations is offered. Taipei, Taiwan, Taiwan 1966
Contract Pharmacal Corp. Contract Pharmacal Corp. Product development, manufacturing and packaging services Hauppauge, United States, United States 1971
Adare Pharma Solutions Adare Pharma Solutions CDMO manufacturing solid drugs Lawrence Township, United States, United States 2015
Suzhou Ze Jing Biological Pharmaceutical Suzhou Ze Jing Biological Pharmaceutical Company developing small molecules & eukaryotic cell based recombinant protein drugs Suzhou, China, China 2009
Halewood Laboratories Halewood Laboratories Provides contract manufacturing services for food, pharmaceuticals, and related products globally. Ahmedabad, India, India 1984
Capsugel Capsugel Dosage forms are delivered for preclinical, clinical, and commercial supply. Morristown, United States, United States 1875
Glukem Glukem Manufactures pellets, micro-pellets, granules, and capsules for pharmaceutical and nutraceutical drugs. Hyderabad, India, India 2014
Vovantis Laboratories Vovantis Laboratories Develops and manufactures novel effervescent drug delivery systems. Vadodara, India, India 2008

Business Activity of Medicaps Limited

Medicaps Limited is engaged in the principal business activity of real estate, with detailed activities including real estate activities with own or leased property.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
L Real Estate L1 Real estate activities with own or leased property Locked
Premium access

Business activity turnover details for Medicaps Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Medicaps Limited

Medicaps Limited is audited by Rawka & Associates (ICAI peer reviewed, certificate valid till 2029-04-30) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
Rawka & Associates (ICAI peer reviewed, certificate valid till 2029-04-30) FY 2026 Declaration of unmodified opinion

Board of Directors of Medicaps Limited

Medicaps Limited is currently managed by 6 directors, with 17 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Alok K Garg
Also directs: Medgel Private Limited
Managing Director 01 Apr 2007 19 Years 4 Months Current
Ramesh Chandra Mittal
Also directs: Trapti Investments Llp, Taurus Dwellers Llp, Saffron Realties Llp and 5 more
Director 06 Aug 1983 43 Years 0 Months Current
Ashok Agrawal Omprakash
Also directs: Medgel Private Limited
Director 25 Jul 2017 9 Years 1 Months Current
Kusum Mittal
Also directs: Trapti Investments Llp, Taurus Dwellers Llp, Saffron Realties Llp
Director 04 May 1991 35 Years 3 Months Current
Dharmendra Solanki Director 05 Feb 2021 5 Years 6 Months Current
Gajendra Singh Director 11 Aug 2023 3 Years 0 Months Current
View all directors

Financials of Medicaps Limited FY 2026 filings available

Medicaps Limited reported revenue of ₹12.45 Cr (down 51.14% YoY) for FY 2026.

Revenue · FY 2026
₹12.45 Cr ▼ 51.14%
Profit · FY 2026
-₹3.04 Cr ▼ 431.96%
Computed EBITDA · FY 2026
-₹1.2 Cr ▼ 233.3%
Revenue₹ Cr · Consolidated0255075FY 2019: ₹54 Cr53.9FY 2019FY 2020: ₹45 Cr · -15.9% YoY45.3-15.9%FY 2020FY 2021: ₹59 Cr · +29.5% YoY58.7+29.5%FY 2021FY 2022: ₹70 Cr · +19% YoY69.9+19%FY 2022FY 2023: ₹49 Cr · -29.3% YoY49.4-29.3%FY 2023FY 2024: ₹27 Cr · -44.6% YoY27.3-44.6%FY 2024FY 2025: ₹25 Cr · -6.8% YoY25.5-6.8%FY 2025FY 2026: ₹12 Cr · -51.1% YoY12.4-51.1%FY 2026
Net Profit₹ Cr · Consolidated-10-5051015FY 2019: ₹5 Cr5.4FY 2019FY 2020: ₹6 Cr (loss) · -208.6% YoY-5.9FY 2020FY 2021: ₹11 Cr · +290.2% YoY11.1+290.2%FY 2021FY 2022: ₹10 Cr · -9.4% YoY10.1-9.4%FY 2022FY 2023: ₹2 Cr · -82.6% YoY1.8-82.6%FY 2023FY 2024: ₹2 Cr (loss) · -227.6% YoY-2.2FY 2024FY 2025: ₹1 Cr (loss) · +74.5% YoY-0.6FY 2025FY 2026: ₹3 Cr (loss) · -432% YoY-3FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year0510Q1'25: ₹6 Cr6.2Q1'25Q2'25: ₹8 Cr8.3Q2'25Q3'25: ₹4 Cr4Q3'25Q4'25: ₹7 Cr7Q4'25Q1'26: ₹3 Cr · -56.6% YoY2.7-56.6%Q1'26Q2'26: ₹2 Cr · -75.7% YoY2-75.7%Q2'26Q3'26: ₹4 Cr · +6.9% YoY4.3+6.9%Q3'26Q4'26: ₹3 Cr · -50.5% YoY3.4-50.5%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue from Operations ₹12.45 Cr ₹25.48 Cr ₹27.35 Cr ₹49.37 Cr ₹69.87 Cr ₹58.72 Cr ₹45.33 Cr ₹53.92 Cr
Other Income ₹8.21 Cr ₹2.73 Cr ₹47.5 Lakh ₹1.6 Cr ₹1.91 Cr ₹58.37 Lakh ₹59.53 Lakh ₹58.43 Lakh
Total Income ₹20.66 Cr ₹28.21 Cr ₹27.82 Cr ₹50.97 Cr ₹71.79 Cr ₹59.3 Cr ₹45.92 Cr ₹54.5 Cr
Cost of Materials Consumed ₹5.44 Cr ₹10.17 Cr ₹8.43 Cr ₹22.05 Cr ₹30.05 Cr ₹31.08 Cr ₹22.33 Cr ₹26.32 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹15.26 Lakh
Changes in Inventories ₹20.01 Lakh ₹48.17 Lakh ₹1.09 Cr ₹85.21 Lakh ₹6.43 Lakh -₹1.71 Cr ₹4.5 Cr -₹13.32 Lakh
Employee Benefit Expense ₹7.74 Cr ₹7.58 Cr ₹7.07 Cr ₹7.69 Cr ₹7.71 Cr ₹6.71 Cr ₹11.04 Cr ₹9.56 Cr
Finance Costs ₹1.3 Lakh ₹2.48 Lakh ₹0 ₹16,000 ₹2,000 ₹0 ₹1.69 Lakh ₹1.8 Lakh
Depreciation & Amortisation ₹1.81 Cr ₹1.72 Cr ₹1.69 Cr ₹1.74 Cr ₹1.81 Cr ₹1.52 Cr ₹1.83 Cr ₹1.81 Cr
Other Expenses ₹8.48 Cr ₹9.07 Cr ₹10.79 Cr ₹13.71 Cr ₹22.09 Cr ₹10.47 Cr ₹12.06 Cr ₹11.27 Cr
Total Expenses ₹23.68 Cr ₹29.05 Cr ₹29.07 Cr ₹46.05 Cr ₹61.73 Cr ₹48.06 Cr ₹51.77 Cr ₹49 Cr
Profit Before Exceptional Items & Tax -₹3.02 Cr -₹84.11 Lakh -₹1.25 Cr ₹4.92 Cr ₹10.06 Cr ₹11.24 Cr -₹5.84 Cr ₹5.5 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax -₹3.02 Cr -₹84.11 Lakh -₹1.25 Cr ₹4.92 Cr ₹10.06 Cr ₹11.24 Cr -₹5.84 Cr ₹5.5 Cr
Total Tax Expense ₹1.41 Lakh -₹27.01 Lakh ₹99.47 Lakh ₹3.05 Cr ₹1.44 Lakh -₹51,000 ₹84,000 ₹11.65 Lakh
Net Profit -₹3.04 Cr -₹57.1 Lakh -₹2.24 Cr ₹1.76 Cr ₹10.08 Cr ₹11.13 Cr -₹5.85 Cr ₹5.39 Cr
  attributable to Owners -₹3.04 Cr -₹57.1 Lakh -₹2.24 Cr ₹1.76 Cr ₹10.08 Cr ₹11.13 Cr ₹0 ₹0
  attributable to NCI ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Other Comprehensive Income -₹6.63 Cr ₹86.43 Lakh ₹4.65 Cr ₹55.95 Lakh ₹1.46 Cr ₹2.63 Cr ₹1.2 Cr ₹0
Total Comprehensive Income -₹9.66 Cr ₹29.33 Lakh ₹2.41 Cr ₹2.32 Cr ₹11.54 Cr ₹13.76 Cr -₹4.65 Cr ₹5.39 Cr
EBITDA (computed) -₹1.2 Cr ₹90.19 Lakh ₹44.05 Lakh ₹6.67 Cr ₹11.87 Cr ₹12.76 Cr -₹4 Cr ₹7.33 Cr
Basic EPS ₹-2.44 ₹-0.46 ₹-1.80 ₹1.50 ₹8.05 ₹11.13 ₹-3.73 ₹4.32
Diluted EPS ₹-2.44 ₹-0.46 ₹-1.80 ₹1.50 ₹8.05 ₹11.13 ₹-3.73 ₹4.32
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Total Assets ₹115.46 Cr ₹125.42 Cr ₹127.28 Cr ₹125.99 Cr ₹130.35 Cr ₹114.82 Cr ₹95.21 Cr ₹106.61 Cr
Non-current Assets ₹68.44 Cr ₹71.99 Cr ₹67.27 Cr ₹65.78 Cr ₹63.66 Cr ₹62.15 Cr ₹62.08 Cr ₹64.61 Cr
Current Assets ₹47.02 Cr ₹53.44 Cr ₹60.01 Cr ₹60.2 Cr ₹66.69 Cr ₹52.67 Cr ₹33.13 Cr ₹42 Cr
Property, Plant & Equipment ₹27.07 Cr ₹27.96 Cr ₹29.43 Cr ₹30.77 Cr ₹31.17 Cr ₹29.98 Cr ₹58.26 Cr ₹58.72 Cr
Inventories ₹2.94 Cr ₹3.2 Cr ₹5.74 Cr ₹7.07 Cr ₹11.85 Cr ₹6.71 Cr ₹5.45 Cr ₹10.94 Cr
Trade Receivables ₹6.92 Cr ₹8.79 Cr ₹10.82 Cr ₹8.46 Cr ₹10.07 Cr ₹6.39 Cr ₹4.41 Cr ₹12.85 Cr
Cash & Equivalents ₹50.31 Lakh ₹41.2 Lakh ₹32.14 Lakh ₹1.11 Cr ₹28,000 ₹22,000 ₹1.25 Cr ₹2.48 Cr
Equity (Net Worth) ₹111.61 Cr ₹121.28 Cr ₹120.98 Cr ₹118.57 Cr ₹116.26 Cr ₹104.71 Cr ₹90.95 Cr ₹95.6 Cr
Equity Share Capital ₹12.47 Cr ₹12.47 Cr ₹12.47 Cr ₹12.47 Cr ₹12.47 Cr ₹12.47 Cr ₹12.47 Cr ₹12.47 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹6.35 Lakh
Borrowings (Current) ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹6.35 Lakh ₹5.8 Lakh
Total Debt (computed) ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹6.35 Lakh ₹12.15 Lakh
Current Liabilities ₹2.71 Cr ₹3.1 Cr ₹5.26 Cr ₹6.39 Cr ₹13.2 Cr ₹9.27 Cr ₹3.37 Cr ₹9.14 Cr
Total Liabilities ₹3.85 Cr ₹4.15 Cr ₹6.3 Cr ₹7.42 Cr ₹14.09 Cr ₹10.11 Cr ₹4.26 Cr ₹11.01 Cr
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow -₹7.02 Cr ₹5.07 Cr ₹6.94 Cr -₹6.08 Cr ₹7.02 Cr
Investing Cash Flow ₹7.11 Cr -₹4.98 Cr -₹7.73 Cr -₹2.56 Cr -₹4.08 Cr
Financing Cash Flow ₹0 ₹0 ₹0 ₹0 ₹0
Capital Expenditure ₹84.64 Lakh ₹32.59 Lakh ₹34.58 Lakh ₹1.16 Cr ₹2.79 Cr
Free Cash Flow (computed) -₹7.87 Cr ₹4.74 Cr ₹6.59 Cr -₹7.24 Cr ₹4.23 Cr
Dividends Paid ₹0 ₹0 ₹0 ₹0 ₹0
Net Change in Cash ₹9.11 Lakh ₹9.06 Lakh -₹79.21 Lakh -₹8.64 Cr ₹2.95 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25
Revenue from Operations ₹3.45 Cr ₹4.3 Cr ₹2.01 Cr ₹2.69 Cr ₹6.96 Cr ₹4.02 Cr ₹8.3 Cr ₹6.19 Cr
Other Income ₹5.59 Cr ₹75.89 Lakh ₹1.53 Cr ₹33.49 Lakh ₹2.14 Cr ₹15.9 Lakh ₹28.62 Lakh ₹14.59 Lakh
Total Income ₹9.04 Cr ₹5.06 Cr ₹3.54 Cr ₹3.02 Cr ₹9.1 Cr ₹4.18 Cr ₹8.58 Cr ₹6.34 Cr
Cost of Materials Consumed ₹1.18 Cr ₹1.29 Cr ₹1.28 Cr ₹1.69 Cr ₹2.72 Cr ₹1.39 Cr ₹2.15 Cr ₹3.91 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories ₹35.72 Lakh ₹61.54 Lakh -₹66.9 Lakh -₹10.35 Lakh ₹5.36 Lakh ₹49.38 Lakh ₹1.78 Cr -₹1.84 Cr
Employee Benefit Expense ₹2.17 Cr ₹1.86 Cr ₹1.85 Cr ₹1.86 Cr ₹2.2 Cr ₹1.79 Cr ₹1.88 Cr ₹1.72 Cr
Finance Costs ₹0 ₹0 ₹0 ₹1.3 Lakh ₹2.48 Lakh ₹0 ₹0 ₹0
Depreciation & Amortisation ₹49.78 Lakh ₹43.68 Lakh ₹43.68 Lakh ₹43.68 Lakh ₹44.12 Lakh ₹42.57 Lakh ₹42.57 Lakh ₹42.57 Lakh
Other Expenses ₹1.8 Cr ₹1.6 Cr ₹2.46 Cr ₹2.62 Cr ₹2.21 Cr ₹2.13 Cr ₹2.03 Cr ₹2.69 Cr
Total Expenses ₹6.01 Cr ₹5.8 Cr ₹5.36 Cr ₹6.51 Cr ₹7.65 Cr ₹6.23 Cr ₹8.27 Cr ₹6.9 Cr
Profit Before Exceptional Items & Tax ₹3.03 Cr -₹73.73 Lakh -₹1.82 Cr -₹3.49 Cr ₹1.45 Cr -₹2.05 Cr ₹31.23 Lakh -₹55.65 Lakh
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹3.03 Cr -₹73.73 Lakh -₹1.82 Cr -₹3.49 Cr ₹1.45 Cr -₹2.05 Cr ₹31.23 Lakh -₹55.65 Lakh
Total Tax Expense -₹1.44 Lakh ₹2.85 Lakh ₹0 ₹0 -₹27.01 Lakh ₹0 ₹0 ₹0
Net Profit ₹3.04 Cr -₹76.58 Lakh -₹1.82 Cr -₹3.49 Cr ₹1.72 Cr -₹2.05 Cr ₹31.23 Lakh -₹55.65 Lakh
  attributable to Owners ₹3.04 Cr -₹76.58 Lakh -₹1.82 Cr -₹3.49 Cr ₹1.72 Cr -₹2.05 Cr ₹31.23 Lakh -₹55.65 Lakh
  attributable to NCI ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Other Comprehensive Income -₹7.88 Cr ₹60.14 Lakh -₹87.61 Lakh ₹1.52 Cr -₹1.6 Cr -₹52.61 Lakh ₹1.39 Cr ₹1.6 Cr
Total Comprehensive Income -₹4.84 Cr -₹16.44 Lakh -₹2.7 Cr -₹1.97 Cr ₹12.25 Lakh -₹2.57 Cr ₹1.7 Cr ₹1.04 Cr
EBITDA (computed) ₹3.53 Cr -₹30.05 Lakh -₹1.38 Cr -₹3.04 Cr ₹1.91 Cr -₹1.62 Cr ₹73.8 Lakh -₹13.08 Lakh
Basic EPS ₹2.44 ₹-0.61 ₹-1.46 ₹-2.80 ₹1.38 ₹-1.64 ₹0.25 ₹-0.45
Diluted EPS ₹2.44 ₹-0.61 ₹-1.46 ₹-2.80 ₹1.38 ₹-1.64 ₹0.25 ₹-0.45
Latest 8 quarters shown.
Segment · Q4 FY26 (latest quarter) Revenue Result (PBIT) Assets Liabilities
Pharma Devision ₹2.92 Cr ₹3.35 Cr ₹48.12 Cr ₹3.22 Cr
Real Estate Devision ₹53.35 Lakh -₹32.73 Lakh ₹67.34 Cr ₹62.82 Lakh
Other ₹0 ₹0 ₹0 ₹0
Segment · FY 2026 (annual) Revenue Result (PBIT) Assets Liabilities
Pharma Devision ₹10.14 Cr -₹2.89 Cr - -
Real Estate Devision ₹2.31 Cr -₹12.46 Lakh - -
Other ₹0 ₹0 - -
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue from Operations ₹2.31 Cr ₹2.42 Cr ₹7.17 Cr ₹10.14 Lakh ₹0 ₹0 ₹11.47 Cr ₹22.49 Cr
Other Income ₹57.65 Lakh ₹56.25 Lakh ₹14.72 Lakh ₹64.46 Lakh ₹60.74 Lakh ₹0 ₹55.15 Lakh ₹26.63 Lakh
Total Income ₹2.88 Cr ₹2.98 Cr ₹7.31 Cr ₹74.6 Lakh ₹60.74 Lakh ₹0 ₹12.03 Cr ₹22.76 Cr
Cost of Materials Consumed ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹5.41 Cr ₹10.5 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹15.26 Lakh
Changes in Inventories ₹33,000 ₹45,000 ₹1.2 Lakh ₹0 ₹0 ₹0 ₹4.53 Cr -₹51.81 Lakh
Employee Benefit Expense ₹1.85 Cr ₹1.81 Cr ₹82.88 Lakh ₹23.27 Lakh ₹45.13 Lakh ₹0 ₹5.88 Cr ₹5.19 Cr
Finance Costs ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹86,000 ₹1.36 Lakh
Depreciation & Amortisation ₹18.58 Lakh ₹16.01 Lakh ₹16.01 Lakh ₹9.23 Lakh ₹9.23 Lakh ₹0 ₹35.54 Lakh ₹35.02 Lakh
Other Expenses ₹96.47 Lakh ₹71.9 Lakh ₹1.48 Cr ₹16.53 Lakh ₹12.46 Lakh ₹0 ₹4.16 Cr ₹6.36 Cr
Total Expenses ₹3.01 Cr ₹2.69 Cr ₹2.49 Cr ₹49.03 Lakh ₹66.82 Lakh ₹0 ₹20.34 Cr ₹22.05 Cr
Profit Before Exceptional Items & Tax -₹12.46 Lakh ₹28.5 Lakh ₹4.83 Cr ₹25.57 Lakh -₹6.08 Lakh ₹0 -₹8.32 Cr ₹70.76 Lakh
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax -₹12.46 Lakh ₹28.5 Lakh ₹4.83 Cr ₹25.57 Lakh -₹6.08 Lakh ₹0 -₹8.32 Cr ₹70.76 Lakh
Total Tax Expense ₹1.41 Lakh -₹27.01 Lakh ₹93.91 Lakh -₹14,000 ₹1.44 Lakh -₹51,000 ₹84,000 ₹11.65 Lakh
Net Profit -₹13.87 Lakh ₹55.51 Lakh ₹3.89 Cr ₹14.64 Lakh -₹3.8 Lakh -₹11.08 Lakh -₹8.33 Cr ₹59.11 Lakh
Other Comprehensive Income -₹49.34 Lakh ₹29.95 Lakh ₹1.49 Cr -₹32.7 Lakh ₹35.69 Lakh ₹1.23 Cr ₹66.41 Lakh ₹0
Total Comprehensive Income -₹63.21 Lakh ₹85.46 Lakh ₹5.38 Cr -₹18.06 Lakh ₹31.89 Lakh ₹1.12 Cr -₹7.66 Cr ₹59.11 Lakh
EBITDA (computed) ₹6.12 Lakh ₹44.51 Lakh ₹4.99 Cr ₹34.8 Lakh ₹3.15 Lakh ₹0 -₹7.95 Cr ₹1.07 Cr
Basic EPS ₹-0.11 ₹0.45 ₹3.12 ₹0.21 ₹-0.06 ₹0.99 ₹-6.14 ₹0.47
Diluted EPS ₹-0.11 ₹0.45 ₹3.12 ₹0.21 ₹-0.06 ₹0.99 ₹-6.14 ₹0.47
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Total Assets ₹67.34 Cr ₹68.03 Cr ₹68.09 Cr ₹61.63 Cr ₹61.81 Cr ₹62.64 Cr ₹61.55 Cr ₹73.78 Cr
Non-current Assets ₹46.2 Cr ₹46.13 Cr ₹46.22 Cr ₹46.42 Cr ₹46.73 Cr ₹47.4 Cr ₹49.15 Cr ₹51.31 Cr
Current Assets ₹21.14 Cr ₹21.9 Cr ₹21.88 Cr ₹15.2 Cr ₹15.07 Cr ₹15.23 Cr ₹12.4 Cr ₹22.47 Cr
Property, Plant & Equipment ₹2.23 Cr ₹2.1 Cr ₹2.26 Cr ₹2.46 Cr ₹2.78 Cr ₹3.26 Cr ₹3.63 Cr ₹3.91 Cr
Inventories ₹2.38 Lakh ₹2.71 Lakh ₹3.16 Lakh ₹0 ₹0 ₹4.94 Lakh ₹53.26 Lakh ₹6.95 Cr
Trade Receivables ₹2.95 Cr ₹3.66 Cr ₹4.65 Cr ₹2.24 Cr ₹2.24 Cr ₹2.41 Cr ₹2.66 Cr ₹6.25 Cr
Cash & Equivalents ₹70,000 ₹5.24 Lakh ₹4.54 Lakh ₹4.05 Lakh ₹9,000 ₹20,000 ₹74.52 Lakh ₹2.13 Cr
Equity (Net Worth) ₹66.71 Cr ₹67.34 Cr ₹66.49 Cr ₹61.11 Cr ₹61.29 Cr ₹60.97 Cr ₹59.85 Cr ₹67.51 Cr
Equity Share Capital ₹12.47 Cr ₹12.47 Cr ₹12.47 Cr ₹12.47 Cr ₹12.47 Cr ₹12.47 Cr ₹12.47 Cr ₹12.47 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹6.35 Lakh
Borrowings (Current) ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹6.35 Lakh ₹5.8 Lakh
Total Debt (computed) ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹6.35 Lakh ₹12.15 Lakh
Current Liabilities ₹22.81 Lakh ₹26.82 Lakh ₹1.17 Cr ₹7.81 Lakh ₹7.62 Lakh ₹1.11 Cr ₹1.03 Cr ₹4.51 Cr
Total Liabilities ₹62.82 Lakh ₹68.27 Lakh ₹1.6 Cr ₹51.79 Lakh ₹51.75 Lakh ₹1.67 Cr ₹1.71 Cr ₹6.27 Cr
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow -₹46.99 Lakh ₹1.85 Cr ₹3.09 Cr -₹2.6 Cr -₹95.08 Lakh
Investing Cash Flow ₹42.45 Lakh -₹1.85 Cr -₹3.09 Cr ₹1.85 Cr ₹1.01 Cr
Financing Cash Flow ₹0 ₹0 ₹0 ₹0 ₹0
Capital Expenditure ₹24.7 Lakh ₹7.12 Lakh ₹0 ₹0 ₹0
Free Cash Flow (computed) -₹71.69 Lakh ₹1.78 Cr ₹3.09 Cr -₹2.6 Cr -₹95.08 Lakh
Dividends Paid ₹0 ₹0 ₹0 ₹0 ₹0
Net Change in Cash -₹4.54 Lakh ₹70,000 ₹49,000 -₹74.63 Lakh ₹5.89 Lakh
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25
Revenue from Operations ₹53.35 Lakh ₹77.28 Lakh ₹99.96 Lakh ₹0 ₹89.08 Lakh ₹26.04 Lakh ₹97.52 Lakh ₹29.02 Lakh
Other Income ₹8.02 Lakh ₹17.32 Lakh ₹97,000 ₹31.33 Lakh ₹26.91 Lakh ₹8.96 Lakh ₹9.66 Lakh ₹10.72 Lakh
Total Income ₹61.37 Lakh ₹94.6 Lakh ₹1.01 Cr ₹31.33 Lakh ₹1.16 Cr ₹35 Lakh ₹1.07 Cr ₹39.74 Lakh
Cost of Materials Consumed ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories ₹8,000 ₹10,000 ₹15,000 ₹0 ₹17,000 ₹6,000 ₹17,000 ₹6,000
Employee Benefit Expense ₹47.02 Lakh ₹46.73 Lakh ₹45.9 Lakh ₹45.67 Lakh ₹44.91 Lakh ₹45.52 Lakh ₹45.38 Lakh ₹45.23 Lakh
Finance Costs ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Depreciation & Amortisation ₹6.58 Lakh ₹4 Lakh ₹4 Lakh ₹4 Lakh ₹4 Lakh ₹4 Lakh ₹4 Lakh ₹4 Lakh
Other Expenses ₹40.42 Lakh ₹12.42 Lakh ₹22.23 Lakh ₹21.41 Lakh ₹23.31 Lakh ₹11.89 Lakh ₹13.09 Lakh ₹23.62 Lakh
Total Expenses ₹94.1 Lakh ₹63.25 Lakh ₹72.28 Lakh ₹71.08 Lakh ₹72.39 Lakh ₹61.47 Lakh ₹62.64 Lakh ₹72.91 Lakh
Profit Before Exceptional Items & Tax -₹32.73 Lakh ₹31.35 Lakh ₹28.65 Lakh -₹39.75 Lakh ₹43.6 Lakh -₹26.47 Lakh ₹44.54 Lakh -₹33.17 Lakh
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax -₹32.73 Lakh ₹31.35 Lakh ₹28.65 Lakh -₹39.75 Lakh ₹43.6 Lakh -₹26.47 Lakh ₹44.54 Lakh -₹33.17 Lakh
Total Tax Expense -₹1.44 Lakh ₹2.85 Lakh ₹0 ₹0 -₹27.01 Lakh ₹0 ₹0 ₹0
Net Profit -₹31.29 Lakh ₹28.5 Lakh ₹28.65 Lakh -₹39.75 Lakh ₹70.61 Lakh -₹26.47 Lakh ₹44.54 Lakh -₹33.17 Lakh
Other Comprehensive Income -₹1.14 Cr ₹22.62 Lakh -₹11.83 Lakh ₹54.25 Lakh -₹25.36 Lakh -₹38.46 Lakh ₹47.32 Lakh ₹46.46 Lakh
Total Comprehensive Income -₹1.46 Cr ₹51.12 Lakh ₹16.82 Lakh ₹14.5 Lakh ₹45.25 Lakh -₹64.93 Lakh ₹91.86 Lakh ₹13.29 Lakh
EBITDA (computed) -₹26.15 Lakh ₹35.35 Lakh ₹32.65 Lakh -₹35.75 Lakh ₹47.6 Lakh -₹22.47 Lakh ₹48.54 Lakh -₹29.17 Lakh
Basic EPS ₹-0.25 ₹0.23 ₹0.23 ₹-0.32 ₹0.57 ₹-0.21 ₹0.36 ₹-0.27
Diluted EPS ₹-0.25 ₹0.23 ₹0.23 ₹-0.32 ₹0.57 ₹-0.21 ₹0.36 ₹-0.27
Latest 8 quarters shown.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Medicaps Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Charges & Borrowings of Medicaps Limited

Open charges
₹20 Lakh
Satisfied charges
₹2.22 Cr
Breakdown by lending institutions
Bank of Baroda₹0.20 Cr
Latest charge details
DateLenderAmountStatus
24 Mar 1992 Bank of Baroda ₹3 Lakh Open
05 Oct 1990 Bank of Baroda ₹10 Lakh Open
24 Jul 1986 Bank of Baroda ₹7 Lakh Open
03 Mar 2018 Axis Bank Limited ₹17.46 Lakh Satisfied
22 Jan 1996 I.D.B.I. Bank Ltd. ₹1.15 Cr Satisfied

Total charge records: 6 View all charges

Employees and EPFO Compliance at Medicaps Limited

View historical data on people associated with Medicaps Limited, including employment history and EPFO contributions.

Premium access

Employee and EPFO history for Medicaps Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Medicaps Limited

Premium access

GST registrations and filing compliance for Medicaps Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Medicaps Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Medicaps Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Medicaps Limited

Premium access

MSME payment history for Medicaps Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Medicaps Limited

Premium access

Corporate group structure for Medicaps Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Medicaps Limited

Premium access

MCA filings and documents for Medicaps Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Medicaps Limited

Activity
18 Sep 2025
Medicaps Limited last Annual general meeting of members was held on 18 Sep 2025 as per latest MCA records.
Activity
31 Mar 2025
Medicaps Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Gwalior.
Directors
11 Aug 2023
Gajendra Singh was appointed as a Director on 11 Aug 2023 & has been associated with this company since 3 years 16 days.
Directors
10 Feb 2022
Abhishek Jain was appointed as a Company Secretary on 10 Feb 2022 & has been associated with this company since 4 years 6 months.
Charges
23 Mar 2021
A charge registered on 03 Mar 2018 via Charge ID 100193845 with Axis Bank Limited was fully satisfied on 23 Mar 2021.
Directors
05 Feb 2021
Dharmendra Solanki was appointed as a Director on 05 Feb 2021 & has been associated with this company since 5 years 6 months.

Frequently Asked Questions about Medicaps Limited

Medicaps Limited is an active public limited company in the pharma sector based in Indore, Madhya Pradesh, India. It was incorporated on 06 August 1983 (43+ years old) and is registered under CIN L70100MP1983PLC002231. Listed on BSE: 523144. The company has 2 employees.

Medicaps Limited reported revenue of ₹12.45 Cr for FY 2026 (down 51.14% YoY) based on consolidated BSE filings.

The current directors of Medicaps Limited are:

The primary industry of Medicaps Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Medicaps Limited is listed on BSE with code 523144.

Yes, Medicaps Limited is recognised as a startup by the Department for Promotion of Industry and Internal Trade (DPIIT).

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available